Contraline, Inc. Press Releases

• Published on July 30, 2025 - 13:00 GMT

  

  Contraline Exercises License Option for NES/T, the First Male Contraceptive to Reach Late-Stage Development

  CHARLOTTESVILLE, VA, UNITED STATES, July 30, 2025 /⁨EINPresswire.com⁩/ -- Contraline, Inc., a clinical-stage biotechnology company developing novel male contraceptives, today announced that it has exercised its option to exclusively license the Nestorone®/ …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...
• Published on April 24, 2025 - 12:00 GMT

  

  Contraline Announces 24-Month Safety and Efficacy Results from First-in-Human Trial of ADAM™

  CHARLOTTESVILLE, VA, UNITED STATES, April 24, 2025 /⁨EINPresswire.com⁩/ -- Contraline, a clinical-stage male contraception company, today announced that participants in the First-in-Human clinical trial of ADAM™ (“The ADAM Study”) have reached a critical …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on April 15, 2025 - 12:02 GMT

  

  Contraline Secures 15th Issued Patent, Reinforcing IP Leadership in Male Contraception

  CHARLOTTESVILLE, VA, UNITED STATES, April 15, 2025 /⁨EINPresswire.com⁩/ -- Contraline, Inc., the leading innovator in male contraception, today announced the issuance of its 15th U.S. patent, further advancing the company’s mission to develop a new …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on July 9, 2024 - 13:00 GMT

  

  Contraline's First In-Human Trial Shows Safety with 12-Month Efficacy Signals of the ADAM™ Male Contraceptive Device

  CHARLOTTESVILLE, VA, UNITED STATES, July 9, 2024 /⁨EINPresswire.com⁩/ -- Contraline, a clinical-stage biotechnology company, has announced promising initial safety and efficacy results from its First-in-Human clinical trial. The trial, which is evaluating …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...